http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2899308-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C321-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6931 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_136634d8dd89ef4a8a595a5ae8e4c549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd8d4910451567a14a35973600f96f4f |
| publicationDate | 2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2899308-T3 |
| titleOfInvention | Lipocationic dendrimers and uses thereof |
| abstract | A dendrimer of the formula: Core-(repeat unit)n-termination group (I) in which the core is bonded to the repeat unit by removal of one or more hydrogen atoms from the core and substitution of the atom of hydrogen by the repeating unit and in which: the nucleus has the formula: **(See formula)** in which: X1 is amino or alkylamino(C<=12), dialkylamino(C<=12), (C<=12)heterocycloalkyl, (C<=12)heteroaryl, or a substituted version thereof; R1 is amino, hydroxy, or mercapto, or (C<=12)alkylamino, (C<=12)dialkylamino, or a substituted version of any of these groups; and a is 1, 2, 3, 4, 5 or 6; or the core has the formula: **(See formula)** where: X2 is N(R5)y; R5 is hydrogen, (C<=18)alkyl, or (<=18)substituted alkyl; and y is 0, 1 or 2, provided that the sum of y and z is 3; R2 is amino, hydroxy, or mercapto, or (C<=12)alkylamino, (C<=12)dialkylamino, or a substituted version of any of these groups; b is 1, 2, 3, 4, 5 or 6; and z is 1, 2, 3; provided that the sum of z and y is 3; or the nucleus has the formula: **(See formula)** where: X3 is -NR6-, where R6 is hydrogen, alkyl(C<=8), or substituted alkyl(C<=18), -O -, or (C<=8)alkylaminodiyl, (C<=8)alkoxy, (C<=8)arendiyl, (C<=8)heteroarendiyl, (C<=8)heterocycloalkanediyl, or a substituted version of any of These groups; R3 and R4 are each independently amino, hydroxy, or mercapto, or (C<=12)alkylamino, di(C<=12)alkylamino, or a substituted version of any of these groups; or a group of the formula: -(CH2CH2N)e(Rc)Rd; in which: e is 1, 2 or 3; Rc and Rd are each independently hydrogen, (C<=6)alkyl, or substituted (C<=6)alkyl; c and d are each independently 1, 2, 3, 4, 5 or 6; or the nucleus is (C<=18)alkylamine), (C<=36)dialkylamine, (C<=12)heterocycloalkane, or a substituted version of any of these groups; wherein the repeat unit comprises a degradable diacyl and a linker; the degradable diacyl group has the formula: **(See formula)** where: A1 and A2 are each independently -O- or -NRa-, where: Ra is hydrogen, (C<=6)alkyl, or substituted (C<=6)alkyl; Y3 is (C<=12)alkanediyl, (C<=12)alkenediyl, (C<=12)arendiyl, or a substituted version of any of these groups; or a group of the formula: wherein: X3 and X4 are (C<=12)alkanediyl, (C<=12)alkenediyl, (C<=12)arendiyl, or a substituted version of any of these groups; Y5 is a covalent bond, (C<=12)alkanediyl, (C<=12)alkenediyl, (C<=12)arendiyl, or a substituted version of any of these groups; and R9 is (C<=8)alkyl or substituted (C<=8)alkyl; the linking group has the formula **(See formula)** where: Y1 is (C<=12)alkanediyl, (C<=12)alkenediyl, (C<=12)arendiyl, or a substituted version of any of these groups; and wherein when the repeating unit comprises a linking group, then the linking group is attached to a degradable diacyl group on both the nitrogen atom and the sulfur atom of the linking group, where the first group of the repeating unit is a degradable diacyl group, where for each linking group, the next group comprises two degradable diacyl groups attached to the nitrogen atom of the linking group; and where n is the number of linker groups present in the repeat unit; and the terminating group has the formula **(See formula)** in which: Y4 is a (C<=18)alkanediyl or a (C<=18)alkanediyl in which one or more of the hydrogen atoms of (C<=18)alkanediyl have been substituted by -OH, -F, -Cl, -Br, -I, -SH, -OCH3, -OCH2CH3, -SCH3, or -OC(O)CH3; R10 is hydrogen, carboxy, hydroxy, or (C<=12)aryl, (C<=12)alkylamino, (C<=12)dialkylamino, (C<=12)N-heterocycloalkyl, -C(O)N( R11)-(C<=6)alkanediyl-(C<=12)heterocycloalkyl, -C(O)-(C<=12)alkylamino, -C(O)-(C<=12)dialkylamino, -C( O)-N-(C<=12)heterocycloalkyl, wherein: R11 is hydrogen, (C<=6)alkyl, or substituted (C<=6)alkyl; wherein the last degradable diacyl in a chain of repeating units is attached to the terminating group; and n is 0, 1, 2, 3, 4, 5 or 6; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2015-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 834.